{"id":"NCT03676192","sponsor":"Celltrion","briefTitle":"To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer","officialTitle":"A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-01","primaryCompletion":"2021-04-22","completion":"2023-09-19","firstPosted":"2018-09-18","resultsPosted":"2025-03-17","lastUpdate":"2025-03-17"},"enrollment":689,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Adenocarcinoma of Lung"],"interventions":[{"type":"DRUG","name":"CT-P16","otherNames":[]},{"type":"DRUG","name":"Avastin","otherNames":[]}],"arms":[{"label":"CT-P16","type":"EXPERIMENTAL"},{"label":"Avastin","type":"ACTIVE_COMPARATOR"}],"summary":"To demonstrate that CT-P16 is similar to EU-Approved Avastin in terms of efficacy as determined by objective response rate (ORR) during the Induction Study Period","primaryOutcome":{"measure":"Objective Response Rate (ORR) During the Induction Study Period From Central Review","timeFrame":"Induction Study Period (around 18 weeks)","effectByArm":[{"arm":"CT-P16","deltaMin":42.4,"sd":null},{"arm":"Avastin","deltaMin":42.07,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":1,"countries":["South Korea"]},"refs":{"pmids":["40795416","36169807"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":69,"n":345},"commonTop":["Alopecia","Anaemia","Nausea","Neutropenia","Asthenia"]}}